-
-
-
-
-
-
-
MAIA Biotechnology (MAIA) Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
-
-
-
-
-
-
-
MAIA Biotechnology (MAIA) Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO
-
-
-
-
-
-
-
MAIA Biotechnology (MAIA) Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
-
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

